Last reviewed · How we verify

oxaliplatin plus capecitabine — Competitive Intelligence Brief

oxaliplatin plus capecitabine (oxaliplatin plus capecitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy combination. Area: Oncology.

marketed Platinum-based chemotherapy combination DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

oxaliplatin plus capecitabine (oxaliplatin plus capecitabine) — LiNing. Oxaliplatin and capecitabine work together as a chemotherapy combination where oxaliplatin cross-links DNA to prevent replication while capecitabine is converted to fluorouracil to inhibit thymidylate synthase and disrupt nucleotide synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
oxaliplatin plus capecitabine TARGET oxaliplatin plus capecitabine LiNing marketed Platinum-based chemotherapy combination DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU)
Oxaliplatin;Capecitabine Oxaliplatin;Capecitabine Hebei Medical University marketed Platinum-based chemotherapy combination; antimetabolite DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU)
atezolizumab + avastin + platinum-based chemotherapy atezolizumab + avastin + platinum-based chemotherapy ARCAGY/ GINECO GROUP phase 3 PD-L1 inhibitor + VEGF inhibitor + platinum-based chemotherapy combination PD-L1, VEGF, DNA (platinum adducts)
TS-1, oxaliplatin TS-1, oxaliplatin Samsung Medical Center phase 3 Fluoropyrimidine + platinum-based chemotherapy combination Thymidylate synthase; DNA (platinum crosslinking)
Oxaliplatin, calcium folinate, 5-fluorouracil Oxaliplatin, calcium folinate, 5-fluorouracil Karolinska University Hospital phase 3 Platinum-based chemotherapy combination (FOLFOX regimen) DNA (oxaliplatin); thymidylate synthase (5-fluorouracil)
Capecitabine & Oxaliplatin Capecitabine & Oxaliplatin Samsung Medical Center phase 3 Antimetabolite and platinum-based chemotherapy combination Thymidylate synthase (capecitabine/5-FU); DNA (oxaliplatin)
Pemetrexed+carboplatin/Cisplatin Pemetrexed+carboplatin/Cisplatin Suzhou Puhe Pharmaceutical Technology Co., LTD phase 3 Antifolate antimetabolite + platinum-based chemotherapy combination Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy combination class)

  1. LiNing · 1 drug in this class
  2. Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). oxaliplatin plus capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/oxaliplatin-plus-capecitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: